Reuters logo
BRIEF-ArgenX launches phase II study of ARGX-110
April 12, 2017 / 5:10 AM / in 8 months

BRIEF-ArgenX launches phase II study of ARGX-110

April 12 (Reuters) - Argen X BV:

* Argenx launches phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

* Phase II clinical trial will enroll up to 10 additional relapsed/refractory CTCL patients

* Primary endpoints of trial are safety and efficacy and secondary endpoints include pharmacokinetics and immunogenicity.

* Interim data are expected by end of 2017

* Expect to report topline data in second half of 2018.

* Phase II clinical trial will be conducted at multiple centers in Europe Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below